Document Detail

Retherapy with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions.
MedLine Citation:
PMID:  23151046     Owner:  NLM     Status:  Publisher    
ABSTRACT Bendamustine and bendamustine/rituximab-combinations have shown high efficacy in relapsed/refractory chronic lymphocytic leukemia (CLL) and indolent B-cell-malignancies (NHL). No data do exist about bendamustine-retherapy after relapse concerning efficacy and toxicity in this patient population. 88 outpatients (57 patients with CLL, 31 patients with NHL) who previously had been treated with bendamustine were retreated with a bendamustine regimen. Treatment consisted of bendamustine (B) or bendamustine + mitoxantrone (BM) or bendamustine + rituximab (BR) or bendamustine + mitoxantrone + rituximab (BMR). Median age was 72 (50-88). A reversible grade 3 or 4 leukocytopenia or thrombocytopenia could be observed in 24% and 13% respectively. Overall response rate (ORR) was 76% (7% CR, 69% PR) with 77% (6% CR, 71% PR) in CLL and 71% (8% CR, 63% PR) in NHL. ORR according to regimen was as follows: B: 57% (14% CR, 43% PR), BM: 70% (4% CR, 66% PR), BR: 55% (10% CR, 45% PR), BMR: 84% (7% CR, 78% PR). Bendamustine retherapy is feasible and achieves high response rates and some long lasting remissions.
Rudolf Weide; Stefan Feiten; Vera Friesenhahn; Jochen Heymanns; Kristina Kleboth; Jörg Thomalla; Christoph van Roye; Hubert Köppler
Related Documents :
24002496 - Phase i study of quizartinib administered daily to patients with relapsed or refractory...
24698676 - Palliative local radiotherapy in the treatment of tumor-stage cutaneous t-cell lymphoma...
25079466 - L-carnitine treatment in a seriously ill cancer patient with severe hyperthyroidism.
23417696 - A phase 2 multicenter study of tivantinib (arq 197) monotherapy in patients with relaps...
17920916 - Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or redu...
9762946 - Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer c...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-14
Journal Detail:
Title:  Leukemia & lymphoma     Volume:  -     ISSN:  1029-2403     ISO Abbreviation:  Leuk. Lymphoma     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007422     Medline TA:  Leuk Lymphoma     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  MMpred: functional miRNA - mRNA interaction analyses by miRNA expression prediction.
Next Document:  Red/green cyanobacteriochromes: sensors of color and power.